Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.
Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses approved BTK inhibitors in B-cell malignancies.
To date, 3 BTK inhibitors have received regulatory approval for use in various B-cell malignancies, says Ghosh.
Ibrutinib (Imbruvica) received FDA approval for treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Ghosh explains. Ibrutinib is also approved for patients with mantle cell lymphoma (MCL) and marginal zone lymphoma who have received at least 1 prior line of therapy, as well as for patients with Waldenström macroglobulinemia.
Furthermore, acalabrutinib (Calquence) is approved for patients with previously untreated and relapsed/refractory CLL/SLL and patients with MCL who have received at least 1 prior line of therapy, says Ghosh.
Currently, zanubrutinib (Brukinsa) is approved for use in patients with MCL after 1 or more prior lines of therapy, Ghosh concludes.